Latest news

• Sanofi backs vaccines unit with €350m Canadian facility

  vaccine Dengvaxia last year, as well as lumpy orders for its meningitis vaccine Menactra and overall static sales of paediatric combination shots. ... Sanofi’s vaccines sales grew 8.3% overall last year, but growth shrank to 1.2% in the fourth-quarter,

• Sanofi taps Evotec for new anti-infectives drive

  stage pipeline setbacks, including big problems for new dengue fever vaccine Dengvaxia.

• Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

  It’s also suffered a couple of major setbacks in its pipeline, including the failure of its dengue vaccine Dengvaxia which had been tipped as a blockbuster but is now looking ... In the Philippines - one of the only countries to use the vaccine

• After some big setbacks, Sanofi talks up its R&D portfolio

  And the annual R&D day comes at a difficult couple of weeks for the company, in the wake of major problems for its dengue fever vaccine Dengvaxia - once tipped as

• Sanofi confirms suspected safety issue with dengue vaccine

  Prospects for Sanofi’s dengue fever vaccine Dengvaxia look increasingly dim after it confirmed a long-debated safety issue with the product. ... That cuts down the eligible patient population for Dengvaxia by some margin, as it is less likely to be